Wednesday 27 September 2023 - 00:08
NOTE: all of our usual telephone and FAX systems are currently down due to a dispute between our landlord and Verizon. We are working to remedy this situation and get our phones back on ASAP.
In the meantime, please use this mobile phone number: 978-715-9327, and this fax number: 781-491-0695.
Thank you for your patience as we work through this unfortunate outage caused by a dispute beyond our control.
Sale: 25% Off !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only - Limited Time Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
D-3307 Dasatinib, Free Base, >99%
Synonyms : [BMS-354825]
Related Terms : [Sprycel]

- Size
- US $
- €
- £
- ¥
- 500 mg
- 39
- 36
- 31
- 5,800
- In stock
- 1 g
- 53
- 49
- 43
- 7,900
- In stock
- 2 g
- 92
- 86
- 75
- 13,700
- In stock
- 5 g
- 135
- 127
- 110
- 20,100
- In stock
- 10 g
- 198
- 186
- 162
- 29,500
- In stock
- 25 g
- 425
- 400
- 348
- 63,300
- In stock
- 50 g
- 740
- 697
- 606
- 110,200
- In stock
- 100 g
- 1,290
- 1,216
- 1,057
- 192,100
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 488.01
- C22H26ClN7O2S
- [302962-49-8]
- M.I. 14: 2829
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.
- More than 830 labs worldwide have purchased Dasatinib from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
- Small molecule inhibitor of both the SRC and BCR/ABL tyrosine kinases, with IC50's for the isolated kinases of 0.55 and 3.0 nM, respectively. Lombardo, L.J., et al. "Discovery of N-(2-chloro-6-methylphneyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in pre-clinical assays." J. Med. Chem. 47: 6658-6661 (2004).
- Dasatinib also inhibits Lyn (IC50 = 8.5 nM) and Src (IC50 = 3.0 nM) kinase activities in vitro using 0.1 mg/mL poly (Glu4-Tyr) as the substrate. Nam, S., et al. "Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells." Cancer Res. 65: 9185-9189 (2005).
- Dasatinib has greater potency than imatinib mesylate and has activity against the majority of kinase mutations in imatinib-resistant chronic myeloid leukemia. Copland, M., et al. "Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction." Blood 107: 4532-4539 (2006).
- Dasatinib and nilotinib are respectively 325-fold (IC50: 0.6 versus 280 nM) and 20-fold (IC50: 15 versus 280 nM) more potent than imatinib against cells expressing wild-type Bcr-Abl. Similar improvements are also seen in all imatinib-resistant mutants tested, with the exception of T315I. Both inhibitors have activity against imatinib-refractory chronic myelogenous leukemia. O'Hare, T., et al. "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants." Cancer Res. 65: 4500-4505 (2005).
- The CAS number for the monohydrate form of dasatinib is [863127-77-9].
- Dasatinib is the active ingredient in the drug product sold under the trade name Sprycel®. This drug has been approved in at least one country for use in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myelogenous leukemia. NOTE: THE DASATINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT SPRYCEL®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
